Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme ...
Pharmaceutical giant Pfizer and French vaccine maker Valneva reported positive topline results from their phase three study ...
New results on Pfizer's Lyme disease vaccine, how the Middle East conflict could strain drug supply chains, and more biotech ...
Pfizer wants to fill a 20-year void in human Lyme disease vaccines, but must win over regulators under a vaccine-skeptical ...
March 23 (Reuters) - Pfizer and Valneva said on Monday their Lyme disease vaccine showed more than 70% efficacy in a ...
An experimental vaccine from Pfizer and Valneva reduced the risk of developing Lyme disease by more than 70%, according to ...
Pfizer and Valneva reported Phase 3 results for their Lyme disease vaccine candidate, with over 70% efficacy. The trial did ...
Pfizer and Valneva announce that a phase 3 trial of the Lyme disease vaccine candidate PF-07307405 shows strong efficacy in adults and children.
Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 ...
Pfizer (NYSE:PFE) has started a Phase 1 trial of a new tafamidis tablet formulation aimed at improving manufacturing ...
In early March 2026, Pfizer reported past Phase 2 trial results showing its investigational trispecific antibody tilrekimig ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results